528 related articles for article (PubMed ID: 26383911)
1. Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines.
Wu Y; Chen X; Ge X; Xia H; Wang Y; Su S; Li W; Yang T; Wei M; Zhang H; Gou L; Li J; Jiang X; Yang J
J Mol Med (Berl); 2016 Feb; 94(2):195-206. PubMed ID: 26383911
[TBL] [Abstract][Full Text] [Related]
2. Amentoflavone protects against psoriasis-like skin lesion through suppression of NF-κB-mediated inflammation and keratinocyte proliferation.
An J; Li Z; Dong Y; Ren J; Huo J
Mol Cell Biochem; 2016 Feb; 413(1-2):87-95. PubMed ID: 26724949
[TBL] [Abstract][Full Text] [Related]
3. Genistein suppresses psoriasis-related inflammation through a STAT3-NF-κB-dependent mechanism in keratinocytes.
Wang A; Wei J; Lu C; Chen H; Zhong X; Lu Y; Li L; Huang H; Dai Z; Han L
Int Immunopharmacol; 2019 Apr; 69():270-278. PubMed ID: 30743203
[TBL] [Abstract][Full Text] [Related]
4. Isoliquiritigenin suppresses IL-1β induced apoptosis and inflammation in chondrocyte-like ATDC5 cells by inhibiting NF-κB and exerts chondroprotective effects on a mouse model of anterior cruciate ligament transection.
Ji B; Guo W; Ma H; Xu B; Mu W; Zhang Z; Amat A; Cao L
Int J Mol Med; 2017 Dec; 40(6):1709-1718. PubMed ID: 29039445
[TBL] [Abstract][Full Text] [Related]
5. Quercetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF-κB pathway.
Chen H; Lu C; Liu H; Wang M; Zhao H; Yan Y; Han L
Int Immunopharmacol; 2017 Jul; 48():110-117. PubMed ID: 28499194
[TBL] [Abstract][Full Text] [Related]
6. Increased βTrCP are associated with imiquimod-induced psoriasis-like skin inflammation in mice via NF-κB signaling pathway.
Li R; Wang J; Wang X; Zhou J; Wang M; Ma H; Xiao S
Gene; 2016 Oct; 592(1):164-171. PubMed ID: 27476970
[TBL] [Abstract][Full Text] [Related]
7. Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells.
Meng Y; Wang M; Xie X; Di T; Zhao J; Lin Y; Xu X; Li N; Zhai Y; Wang Y; Li P
Int J Mol Med; 2017 May; 39(5):1101-1110. PubMed ID: 28339016
[TBL] [Abstract][Full Text] [Related]
8. NF-κB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH.
Andrés RM; Montesinos MC; Navalón P; Payá M; Terencio MC
J Invest Dermatol; 2013 Oct; 133(10):2362-2371. PubMed ID: 23594598
[TBL] [Abstract][Full Text] [Related]
9. PDRN, a Bioactive Natural Compound, Ameliorates Imiquimod-Induced Psoriasis through NF-κB Pathway Inhibition and Wnt/β-Catenin Signaling Modulation.
Irrera N; Bitto A; Vaccaro M; Mannino F; Squadrito V; Pallio G; Arcoraci V; Minutoli L; Ieni A; Lentini M; Altavilla D; Squadrito F
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059361
[TBL] [Abstract][Full Text] [Related]
10. Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-κB Signaling Pathways.
Guo H; Li M; Liu H
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216231
[TBL] [Abstract][Full Text] [Related]
11. PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines.
Dou R; Liu Z; Yuan X; Xiangfei D; Bai R; Bi Z; Yang P; Yang Y; Dong Y; Su W; Li D; Mao C
PLoS One; 2017; 12(5):e0176823. PubMed ID: 28464025
[TBL] [Abstract][Full Text] [Related]
12. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways.
Xu J; Duan X; Hu F; Poorun D; Liu X; Wang X; Zhang S; Gan L; He M; Zhu K; Ming Z; Chen H
J Dermatol Sci; 2018 Feb; 89(2):127-135. PubMed ID: 29137840
[TBL] [Abstract][Full Text] [Related]
13. Formula PSORI-CM01 inhibits the inflammatory cytokine and chemokine release in keratinocytes via NF-κB expression.
Han L; Sun J; Lu CJ; Zhao RZ; Lu Y; Lin HJ; Wei JA
Int Immunopharmacol; 2017 Mar; 44():226-233. PubMed ID: 28129604
[TBL] [Abstract][Full Text] [Related]
14. The potential of Diosgenin in treating psoriasis: Studies from HaCaT keratinocytes and imiquimod-induced murine model.
Wu S; Zhao M; Sun Y; Xie M; Le K; Xu M; Huang C
Life Sci; 2020 Jan; 241():117115. PubMed ID: 31790685
[TBL] [Abstract][Full Text] [Related]
15. Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-κB/MAPK pathway.
Liu A; Zhao W; Zhang B; Tu Y; Wang Q; Li J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32515468
[TBL] [Abstract][Full Text] [Related]
16. Isoliquiritigenin inhibits TNF-α-induced release of high-mobility group box 1 through activation of HDAC in human intestinal epithelial HT-29 cells.
Chi JH; Seo GS; Cheon JH; Lee SH
Eur J Pharmacol; 2017 Feb; 796():101-109. PubMed ID: 28012970
[TBL] [Abstract][Full Text] [Related]
17. Isoliquiritigenin exerts antioxidative and anti-inflammatory effects via activating the KEAP-1/Nrf2 pathway and inhibiting the NF-κB and NLRP3 pathways in carrageenan-induced pleurisy.
Gao Y; Lv X; Yang H; Peng L; Ci X
Food Funct; 2020 Mar; 11(3):2522-2534. PubMed ID: 32141447
[TBL] [Abstract][Full Text] [Related]
18. Protectin D1 reduces imiquimod-induced psoriasiform skin inflammation.
Park KD; Kim N; Kang J; Dhakal H; Kim JY; Jang YH; Lee WJ; Lee SJ; Kim SH
Int Immunopharmacol; 2021 Sep; 98():107883. PubMed ID: 34153674
[TBL] [Abstract][Full Text] [Related]
19. Isoliquiritigenin alleviated the Ang II-induced hypertensive renal injury through suppressing inflammation cytokines and oxidative stress-induced apoptosis via Nrf2 and NF-κB pathways.
Xiong D; Hu W; Ye ST; Tan YS
Biochem Biophys Res Commun; 2018 Nov; 506(1):161-168. PubMed ID: 30340829
[TBL] [Abstract][Full Text] [Related]
20. Isoliquiritigenin protects against angiotensin II-induced fibrogenesis by inhibiting NF-κB/PPARγ inflammatory pathway in human Tenon's capsule fibroblasts.
Ye H; Yang X; Chen X; Shen L; Le R
Exp Eye Res; 2020 Oct; 199():108146. PubMed ID: 32726604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
